David Gregory, PhD
Dr Gregory is a molecular biologist with over 15 years’ experience in innate immunity and infectious disease. A 2020 recruit to VIC, he works closely with biotech colleagues and both internal and external scientific teams to conduct key preclinical and IND enabling studies in VIC’s translational programs. He also leads early stage discovery projects in VIC’s COVID portfolio.
Dr Gregory has an extensive background in applying genome-scale analyses to neglected and emerging infectious disease. His postdoctoral studies focused on the effects of infection with a neglected tropical parasite on gene expression, and how this influences clinical outcome. He then spent 10 years at Harvard T.H. Chan School of Public Health as lead scientist in Department of Defence sponsored target and biomarker discovery campaigns. He developed genomic and bioinformatic screening platforms to identify genes that make people susceptible to respiratory pathogens and applied these techniques to the innate immune responses to emerging and neglected pathogens such as the bacteria that cause plague, anthrax, tularemia, and tuberculosis. At MGH, he previously led a cross- functional data analysis and interpretation team in a consortium to develop a novel therapeutic paradigm for fatal systemic inflammation. He now applies this experience to VIC’s complex, data-intense programs and studies of COVID immunology.